Risk factors and chronology of infection in solid organ transplantation;Factores de riesgo y cronologia de la infeccion en el trasplante de organo solido

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 15, Issue SUPPL. 2, 1997, Pages 3-11

  Gavaldà, Joan ^a   Pahissa, Albert ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONOLOGY; HUMAN; INFECTION; ORGAN TRANSPLANTATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPAIN; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; DONOR; EQUIPMENT; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; POSTOPERATIVE COMPLICATION; TIME; TRANSPLANTATION;

DISEASE SUSCEPTIBILITY; EQUIPMENT CONTAMINATION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; INFECTION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TIME FACTORS; TISSUE DONORS; TRANSPLANTATION;

EID: 0030913164     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Ho M. Cytomegalovirus: Biology and infection, 2a. ed. Nueva York: Plenum Medical Book Co, 1991.
2. Kubin RH. Infection in the organ transplant recipient. En: Rubin RH, Young LS, eds. Clinical approach of the infection in the compromised host. Nueva York: Plenum Medical Book Company, 1994; 629-705.
3. Wright TL, Pereira B. Liver transplantation for chronic viral hepatitis. Liver Transplant Surgery 1995; 1: 30-42.
4. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP et al. Liver transplantation in European patients with hepatitis B surface antigen. N Engl J Med 1993; 329: 1.842-1.847.
5. Ferrell LD, Wright TL, Roberts J, Ascher N, Lake J. Hepatitis C viral infection in liver transplant recipients. Hepatology 1992; 16: 865-876.
6. Scroggs MW, Wolfe JA, Bollinger RR, Sanfilippo F. Cause of death in renal transplant recipients: a review of autopsy findings from 1996 through 1985. Arch Pathol Lab Med 1987; 111: 983-987.
7. Castaldo P, Stratta RJ, Wood RP, Markin RS, Patil KD, Shaefer MS et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg 1991; 126: 149-156.
8. Kusne S, Dummer JS, Singh N, Iwatsuki S, Makowka L, Esquivel C et al. Infections after liver transplantation: an analysis of 101 consecutive cases. Medicine 1988; 67: 132-143.
9. Horvath J, Dummer S, Loyd J, Walker B, Merrill WH, Frist WH et al. Infection in the transplanted and native lung after single lung transplantation. Chest 1993; 104: 681-685.
10. Colonna JO II, Winston DJ, Brill JE, Goldstein Ll, Hoff MP, Hiatt JR et al. Infectious complications in liver transplantation. Arch Surg 1988; 123: 360-364.
11. Wade JJ, Rolando N, Hayllar K, Philpott-Howard J, Casewell MW, Williams R et al. Bacterial and fungal infections after liver transplantation: an analysis of 284 patients. Hepatology 1995; 21: 1.328-1.336.
12. Bando K, Paradis IL, Keenan RJ, Yousem SA, Komatsu K, Konishi H et al. Analysis of time-dependent risks for infection, and death after pulmonary transplantation. J Thor Cardiovasc Surg 1995; 109: 49-57.
13. Gustafson TL, Schaffner W, Lavely GB, Stratton CW, Johnson HK. Invasive aspergillosis in renal transplant recipients: correlation with corticosteroid therapy. J Infect Dis 1983; 148: 230-238.
14. Corensek MJ, Stewart RW, Keys TF, Mehta AC, McHenry MC, Goormastic M. A multivariate analysis of risk factors for pneumonia following cardiac transplantation. Transplantation 1988; 46: 860-865.
15. Ho M, Wajszczuk CP, Hardy A. Infections in kidney, heart and liver transplant recipients on cyclosporine. Transplant Proc 1983; 15: 2.768-2.772.
16. Lebeau G, Yanaga K, Marsh JW, Tzakis AG, Makowka L, Gordon RD et al. Analysis of surgical complications after 397 hepatic transplantations. Surgery 1990; 170: 317-322.
17. Paya CV, Wiesner RH, Hermans PE, Larson-Keller JJ, Ilstrup DM, Krom RA et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J Hepatol 1993; 18: 185-195.
18. Mancini MC, Tauxe WM. Assessment of pulmonary clearange in heart-lung transplant recipients using technitium 99 mini-micronized albumin colloid (MMAC). Am Rev Respir Dis 1987; 135: A111.
19. Rossman CM, Dolovich M, Dolovich J, Wilson W, Newhouse M. Mucociliary clearance. Am Rev Respir Dis 1975; 112: 744-748.
20. Shankar S, Fulsham L, Read RC, Theodoropoulos S, Cole PJ, Madden B et al. Mucociliary function after lung transplantation. Transplant Proc 1991; 23: 1.222-1.223.
21. Read RC, Shankar S, Rutman A, Feldman C, Yacoub M. Ciliary beat frequency and structure of recipient and donor epithelia following lung transplantation. Eur Respir J 1991; 4: 796-801.
22. Herve P, Silbert D, Cerrina J, Simonneau G, Dartevelle P. Impairment of bronchial mucociliary clearance in long-term survivors of heart/lung and double-lung transplantation. Chest 1993; 103: 59-63.
23. Paradis IL, Marrari M, Zeevi A, Duquesnoy RJ, Griffith BP et al. HLA phenotype of lung lavage cells following heart-lung transplantation. J Heart Transplant 1985; 4: 422-425.
24. Zenati M, Dowling RD, Yousem SA, Hardesty RL, Griffith BP, Casarotto D et al. Influence of the donor lung on development of early infections in lung transplant recipients. J Heart Transplant 1990; 9: 502-508.
25. Duncan AJ, Dummer JS, Paradis IL, Dauber JH, Yousem SA. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant 1991; 10: 638-646.
26. Saxon A, Stevens RH, Ramer SJ, Clements PJ, Yu DT. Glucocorticoids administered in vivo inhibit human suppressor T lymphocyte function and diminished B lymphocyte responsiveness in in vitro immunoglobulin synthesis. J Clin Invest 1978; 61: 922-930.
27. Fauci A, Dale D, Balow J. Glucocorticosteroid therapy: mechanism of action and clinical considerations. Ann Intern Med 1976; 84: 304.
28. Haynes BF, Fauci AS. The differential effect of in vivo hydrocortisone on the kinetics of subpopulations of human peripheral blood-derived lymphocytes. Blood 1975; 46: 235-243.
29. Gillis S, Crabtree GR, Smith KA. Glucocorticoid induced inhibition of T cell growth factor production. J Immunol 1979; 123: 1.632.
30. Walker PR, Moorhead JF. Infection in the renal transplant patient. J R Soc Med 1978; 71: 84-86.
31. Rifkind D, Marchioro T, Schneck SA, Hill RB Jr. Systemic fungal infections complicating renal transplantation and immunosuppressive therapy. Am J Med 1967; 43: 28-38.
32. Bach MC, Adler JL, Breman J, P'eng FK, Sahyoun A, Schlesinger RM. Influences of rejection therapy in fungal and notarial infections in renal-transplant recipients. Lancet 1973; 1: 180-184.
33. Anderson RJ, Schafer LA, Olin DB, Eickhoff TC. Infectious risk factors in the immunosuppressed host. Am J Med 1973; 54: 453-460.
34. The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation: analysis at three years. N Engl J Med 1986; 314: 1.219.
35. Halasz NA, Gamboa EA, Ward DM, Steiner RW, Brosther OL. Kidney transplantation in the cyclosporine era. Arch Surg 1987; 122: 1.001.
36. Iwatsuki S, Starzl TE, Todo S, Gordon RD, Tzakis AG. Experience in 1000 liver transplantation under cyclosporine-steroid therapy: a survival report. Transplant Proc 1988; 20 (Supl I): 498.
37. Oyer PE, Stinson EB, Miller DC, Jamieson SW, Mitchell RS, Shumway NE et al. Cyclosporine in cardiac transplantation: a 2 1/2 year follow-up. Transplant Proc 1983; 15 (Supl 1): 2.546.
38. Macoviak JA, Oyer PR, Stinson EB, Jamieson SW. Four-year experience with cyclosporine for heart and heart-lung transplantation. Transplant Proc 1985; 17 (Supl 2): 97.
39. Simmons RC, Abress LK. Quality of life on cyclosporine versus conventional therapy. Transplant Proc 1987; 19: 1.860.
40. Bunjes D, Hardt C, Rollinghoff M, Wagner IL Cyclosporine mediates immunosuppression of primary cytotoxicT cell responses by impairing the release of interleukin-1 and interleukin-2. Eur J Immunol 1981; 2: 657.
41. Hess Ad, Tutschka PJ, Santos GW. Effect of cyclosporine A on human lymphocyte responses in vitro. III. CyA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but docs not inhibit the response of primed lymphocytes to TCGF. J Immunol 1982; 128: 335.
42. Cohen DJ, Loerscher R, Rubin MF, Tilney NL, Carpenter CB, Strom TB et al. Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med 1984; 101: 667.
43. Kalman VK, Kumpel GR. Cyclosporin A inhibitis the production of gamma interferon, but does nos inhibit production of virus-induced IFN alpha/betha. Cell Immunol 1983; 78: 122.
44. Borel R, Ruffel B. The mechanism of action of cycles porin: a continuing puzzle. En: Schindler R, ed. Cyclosporine in autoimmune diseases. Berlin: Springer-Verlag, 1986; 24.
45. Berger R, Meingassner JG, Knapp W. In vitro effects of Cyclosporin A on human B-cell responses. Scand J Immunol 1983; 17: 241.
46. Paavonen T, Hayry R. Effect of Cyclosporin A on T-dependent and independent immunoglobulin synthesis in vitro. Nature 1980; 287: 542.
47. Thompson AW, Deborah K, Moon C, Carolyn L, Greczy L, Nelson DS. Cyclosporin A inhibits lymphokine production but not the response of macrophages to lymphokines. Immunology 1983; 48: 291.
48. Janco RL, English D. Cyclosporin and human neutrophil function. Transplantation 1983; 35: 501.
49. Dummer JS, Hardy A, Poorsattar A, Ho M. Early infections in kidney, heart and liver transplant recipients on cyclosporine. Transplantation 1983; 36: 259-267.
50. Starzl TE. Klintmalm GBG, Weil R III, Porter KA, Iwatsuki S, Schroter GP et al. Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients. Surg Gynecol Obstet 1931; 153: 486-494.
51. Mason JW, Stinson EB, Hunt SA, Schroeder JS, Rider AK. Infections after cardiac transplantation: relation to rejection therapy. Ann Intern Med 1976: 85: 69-72.
52. Najarian JS, Fryd DS, Strand M, Canafax DM, Ascher NL, Payne WD. A single institution, randomized, prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients Ann Surg 1985; 201: 142-157.
53. Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1983; 309: 809-815.
54. European Multicentre Trial. Cyclosporin A as a sole immunosuppressive agent in recipients of kidney allografts from cadaver donors. Lancet 1982; 2: 57-60.
55. Andreone PA, Olivari MT, Elick B, Arentzen CE, Sibley RK. Reduction of infectious complications following heart transplantation with triple-drug immunotherapy. J Heart Transplant 1986; 5: 13-19.
56. Thomason AW. FK-506-How much potential? Immunol Today 1990; 11: 6-9.
57. Harding MW, Galat A, Uehling DE, Schreiber SL. A receptor for the immunosuppressant FK-506 is a cistrans peptidyl-propylisomerase. Nature 1989; 341: 758.
58. Fre TH, Albers MW, Galat A, Verdine GL. Rapamycin and FK 506 binding proteins (immunophillins). J Am Chem Soc 1991; 113: 1.409.
59. Anderson J, Nagy S, Groth CG, Anderson U. Effects of FK 506 and cyclosporine A on cytokine production studied in vitro at single-cell level. Immunology 1992; 75: 136.
60. Fruman DA, Klee CB, Bierer BE, Burakolf SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA 1992; 9: 3.686.
61. Yoshimura N, Matsui S, Hamashima T, Oka T. Effect of a new immunosuppressive agent FK 506 on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of allorreactivity. Transplantation 1989; 47: 351.
62. Wang SC, Zeevi A, Jordan ML, Simmons RL, Tweardy DJ. FK 506, rampycin and cyclosporine: effects on IL-4 and IL-10 MRNA levels in a T-helper 2 cell line. Transplant Proc 1991; 23: 2.920.
63. Kimball P, Kerman RH, Williams J, Kahan BD. Cyclosporine and rapamycin block protein kinase C-mediated induction of the activation signal, activator of DNA replication, in cell-free assay. Transplant Proc 1993; 25: 518-519.
64. Maki N, Sekiguch E, Hishima FI, Fukasawa M. Complementary DNA enconding the human T-cell FK-506 binding protein, a peptidyprolyl cis-trans isomerase distint from cyclophillin. Proc Natl Acad Sci USA 1990; 87 (14): 5.440.
65. Bierer B, Screiber SL, Burakoff SJ. The effect of the immunosuppressant FK-506 on alternase pathways of T-cell activation. Eur J Immunol 1991; 21: 439.
66. Metcalfe SM, Richards FM, Cyclosporine, FK 506, and rapamycin. Some effects and early activation events in serum-free, mitogen-stimulated mouse spleen cells. Transplantation 1990; 49: 798.
67. Tocci MJ, Matkovich DA, Collier KS, Kwok P, Dumont F, Lin S. The immunosuppressant FK-506 actively inhibit expression of early T cell activation genes. J Immunol 1989; 143 (2): 718.
68. Eiras G, Shimizu Y, van Seventer GA, Duquesnoy RJ, Zeevi A. Effects of FK 506 and cyclosporine on T-cell activation: integrin-mediated adhesion of T-cells, proliferation and maduration of cytotoxic T-cells. Transplant Proc 1991; 23: 936.
69. Bierer B, Schreiber SI, Burakoff SJ. Mechanisms of immunosuppression by FK 506. Preservation of T-cell transmembrane signal transduction. Transplantation 1990; 49: 1.168.
70. Todo S, Fung JJ, Tzakis A, Demetris AJ, Jain A, Alessiani M et al. One hundred ten orthotopic liver transplant under FK-506 in adults. Transplant Proc 1991; 23: 1.397.
71. Todo S, Fung JJ, Starzl TE, Tzakis A, Doyle H, Abu-Elmagd K. Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg 1994; 220: 297-308.
72. McMaster P, Mayer D, Neuhaus P, Neuberger JM. Patient and graft survival in the European multicentre liver study comparing FK-506 with cyclosporine [resumen]. 6th Congress of the European Society for Organ Transplantation. Rodas, 25-28 de octubre, 1993.
73. McDiarmid SV, Busuttil RW, Ascher NL, Burdick J. D'Alessandro AM, Esquivel C. FK506 (tracromilus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial. Transplantation 1995; 59: 530-536.
74. The U.S. Multicentcr FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1.110-1.115.
75. Alesiani M, Kusne S, Martin FM et al. Infections with FK 506 immunosuppression: preliminary results with primary therapy. Transplant Proc 1990; 22 (Supl 1): 44.
76. Staschak S, Wagner S, Block G. Van Thiel DH, Jain A, Fung J. A cost comparison of liver transplantation with FK506 or cyclosporine as the primary immunosuppressive agent. Transplant Proc 1990; 22 (Supl 1): 47.
77. Griffith BP, Bando K, Hardesty RL, Armitage JM, Keenan RJ, Pham SM. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation 1994; 57: 848-851.
78. Bach JF, Strom TB. The mode of action of immunosuppressive agents. Amsterdam: Elsevier, 1985.
79. Novick AC, Braun WE, Stinmulier D, Flechner SM. A controlled, randomized, double-blind study of antilymphoblast globulin in cadaveric renal transplantation. Transplantation 1983; 35: 175.
80. Cosimi AB. The clinical value of antilymphocite antibodies. Transplant Proc 1981; 13: 462.
81. Kung PC, Goldstein G, Reinherz EL, Schosman SF. Monoclonal antibodies defining distinctive human T cell antigens. Science 1979; 206: 347.
82. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337.
83. Cocimi AB, Burton RC, Colvin RB. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32: 535.
84. Cosimi AB, Cho SI, Delmonico FK, Kaplan MM, Rohrer RJ, Jenkins RL. A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection. Transplantation 1987; 43: 91.
85. Kremer A. Barbes L, Hirsch, Goldstein G. Orthochone OKT3 monoclonal antibody reserval of hepatic, cardiac allograft rejection unresponsive to conventional immunosuppressive treatment. Transplant Proc 1987; 19: 54.
86. Bristow MR, Gilbert EM, O'Connell JB, Renlund DG, Watson FS, Hammond E. Use of OKT3 monoclonal in cardiac transplantation: review of the initial experience. J Heart Transplant 1988; 7: 1.
87. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, Schooley RT, Isaacson D, Doran M. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992;53:68-72.
88. Portela D, Patel R, Larson-Keller JJ, Ilstrup DM, Wiesner RH, Steers JL. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995; 171: 1.014-1.018.
89. Aguado JM, Gomez-Sánchez MA, Lumbreras C, Delgado J, Lizasoain M, Otero JR. Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3. Antimicrob Agents Chemother 1995; 39: 1.643-1.645.
90. Lumbreras C, Otero JR, Aguado JM, Lizasoain M, Gómez R, García I. Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies. Antimicrob Agents Chemother 1993; 37: 2.490-2.492.
91. Bieber CP, Herbeling RL, Jamieson SW. Lymphoma in cardiac transplant recipients associated with cyclosporin A, prednisone and anti-thymocyte globulin (ATG). En: Purtilo DT, ed. Immune Deficiency and Cancer. Nueva York: Plenum Press, 1984; 309-320.
92. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990; 323: 1.723-1.769.
93. Singh N, Dummer JS, Kusne S, Breinig MK, Armstrong JA, Makowka L. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988; 158: 124-131.
94. Canfield CW, Hundnali SD, Colonna JO. Fulminant Epstein-Barr virus-associated post-transplant lymphoproliferative disorders following OKT3 therapy. Clin Transplant 1992; 6: 1-9.
95. Denning DW, Weiss LM, Martinez K, Flechner SM. Transmission of Epstein-Barr virus by a transplanted kidney, with activation by OKT3 antibody. Transplantation 1989; 48: 141-144.
96. Kormos RL, Armitage JM, Dummer JS, Miyamoto Y, Griffith BP, Hardesty RL et al. Optimal perioperative immunossupression in cardiac transplantation using rabbit antithymocyte globulin. Transplantation 1990; 49: 306-311.
97. Frey DJ, Matas AJ, Gillingham KJ, Canafax D, Payne WD, Dunn DL. Sequential therapy-A prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. Transplantation 1992; 54: 50-56.
98. Menkis AH, Powell AM, Novick R, McKenzie FN, Kostuk WJ, Pflugfelder PW. A prospective randomized controlled trial of initial immunosuppression with ALG versus OKT3 in recipients of cardiac allografts. J Heart Lung Transplant 1992; 11: 569-576.
99. Renlund DG, O'Connell JB, Gilbert EM, Hammond ME, Burton NA, Jones KW. A prospective comparison of murine monoclonal CD3 (OKT3) antibody-based and esquine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Transplantation 1989; 47: 599-605.
100. Fulton B, Markhalm A. Mycophenolate Mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996; 51: 278-298.
101. European Mycophenolate Mofetil Cooperative Study Group. Placebo controlled study of Mycophenolate Mofetil combined with cyclosporine and corticosteroids in the prevention of acute rejection. Lancet 1995; 345: 1.321-1.325.
102. Michaels MG, Green M, Wald ER, Starzl TE. Adenovirus infection in pediatric liver transplant recipients. J Infect Dis 1992; 165: 170-174.
103. Pohl C, Green M, Wald ER, Ledesma-Medina J. Respiratory syncytial virus infection in pediatric liver transplant recipients. J Infect Dis 1992; 165: 166-169.
104. Panuska JR, Hertz MI, Taraf H, Villani A, Cirino NM. Respiratory syncytial virus infection of alveolar macrophages in adult transplant patients. Am Rev Respir Dis 1992; 145: 934-939.
105. Apaisch AM, Green M, Wald ER. Influenza and parainfluenza virus infections in pediatric organ transplant recipients. [resumen 28]. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, 1992.
106. Luft BJ, Naot Y, Araujo FG, Stinson EB, Remington JS. Primary and reactivated toxoplasma infection in patients with cardiac transplants. Ann Intern Med 1983; 99: 27-31.
107. Dummer JS, Armstrong J, Somers J, Kusne S, Carpenter BJ, Rosenthal JT. Transmission of infection with herpes simplex virus by renal transplantation. J Infect Dis 1987; 155: 202-206.
108. Cen H, Breinig MC, Atchison RW, Ho M, McKnight JL. Epstein-Barr virus transmission via the donor organs in solid organ transplantation: polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3, and IR4. J Virol 1991; 65: 976-980.
109. Wolf JL, Perkins HA, Schreeder MT, Vincenti F. The transplanted kidney a source of hepatitis B infection. Ann Intern Med 1979; 91: 412-413.
110. Pereira BJG, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. N Engl J Med 1991; 325: 454-460.
111. Dummer JS, Erb S, Breinig MK, Ho M, Rinaldo CR Jr, Gupta P. Infection with human immunodeficiency virus in the Pittsburgh transplant population: a study of 583 donors and 1043 recipients, 1981-86. Transplantation 1989; 47: 134-139.
112. Centers for Disease Control and Prevention. Human immunodeficiency virus infection transmitted from an organ donor screened for IHV antibody. MMWR 1987; 36: 306-308.
113. Kumar P, Pearson JE, Martin DH, Leech SH, Buisseret PD, Bezbak HC. Transmission of human immunodeficiency virus by transplantation of a renal allograft with development of the acquired immunodeficiency syndrome. Ann Intern med 1987; 106: 244-245.
114. Gottesdiener KM. Transplant infections: donor-to-host transmission with the allograft. Ann Intern Mcd 1989; 110: 1.001-1.116.
115. Nelson PW, Delmonico FL, Tolkoff-Rubin NE, Cosimi AB, Fang LS, Russell PS. Unsuspected donor Pseudomonas infection causing arterial disruption after renal transplantation. Transplantation 1984; 37: 313-314.
116. McCoy GC, Loening S, Braun WE, Magnusson MO, Banowsky LH, McHenry MC et al.The late of cadaver renal allografts contaminated before transplantation. Transplantation 1975; 20: 467-472.
117. Doig RL, Boyd PJR, Eykyn S. Staphylococcus aureus transmitted in transplantation kidneys. Lancet 1975; 2: 243-244.
118. McLeish KR, McMurray SD, Smith EJ, Filo RS. The transmission of Candida albicans by cadaveric allografts. J Urol 1977; 118: 513.
119. Anderson CB, Haid SD, Hruska KA, Etheredge EA. Significance of microbial contamination of stored cadaver kidneys. Arch Surg 1978; 113: 269-271.
120. Hayry P, Renkonen O-V. Frequency and late of human renal allografts contaminated prior to trasplantation. Surgery 1979; 85: 404-407.
121. McCoy GC, Loening S, Braun WE, Munda R, Fidler JP, Craycraft TK. The late of cadaver renal allografts contaminated before transplantation. Transplantation 1975; 20: 467-472.
122. Majeski JA, Alexander JW, First MR, Reinmuth B et al. Transplantation of contaminated cadaver kidneys. Arch Surg 1982; 117: 221-224.
123. Spees EK, Ligh JA, Oakes DD. Experience with cadaver renal allograft contamination before transplantation. Br J Surg 1982; 69: 482-485.